Sign up USA
Proactive Investors - Run By Investors For Investors

TransEnterix shares pop after FDA clears robotic surgery instruments

The FDA’s clearance of the 3 millimeter diameter instruments will allow the company’s Senhance robotic surgery system to be used for microlaparoscopic surgeries
FDA approved button on PC keyboard
The addition of 3 millimeter instruments will allow high-volume surgeries with even smaller incisions

The medical device company TransEnterix (NYSEAMERICAN:TRXC) is on the receiving end of good news from the US Food and Drug Administration which has awarded 510(k) clearance for its 3 millimeter as well as additional 5 millimeter Senhance system instruments.

The FDA’s clearance of the 3 millimeter diameter instruments will pave the way for the company’s Senhance robotic surgery system to be used for microlaparoscopic surgeries that enable surgeons to operate through tiny incisions that don’t leave patients with severe scarring.

Investors also welcomed the FDA’s move, sending Transenterix shares up 13% to $5.06 before Thursday’s opening bell.

READ:TransEnterix posts bigger 2Q loss although revenue tops expectation

Todd Pope, CEO of TransEnterix, said the FDA’s acceptance of its 3 millimeter instruments represents an “unparalleled shift” in robotic surgery.

“The addition of 3 millimeter instruments will allow many high volume surgeries to be performed with smaller incisions, which supports our mission of advancing minimally invasive surgical capabilities within digital laparoscopy,” Pope said in a statement.

Based in Morrisville, North Carolina, TransEnterix is a pioneer in the use of robotics to advance minimally-invasive surgery.

Contact Ellen Kelleher at [email protected]

View full TRXC profile View Profile

TransEnterix Inc. Timeline

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use